Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04024007
Other study ID # CHUB-citrate
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2019
Est. completion date December 1, 2023

Study information

Verified date March 2022
Source Brugmann University Hospital
Contact Sébastien Redant, MD
Phone 3224773100
Email Sebastien.REDANT@chu-brugmann.be
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Citrate anticoagulation is becoming the gold standard in dialysis in intensive care units. It is now accepted that citrate prolongs the life of filters with a lower risk of bleeding. However, the management of citrate is complex. Optimization is based on citrate flow, blood flow and the amount of calcium reinjected. Frequently the citrate level is sub-dosed.Currently, the fraction of excretion of citrate by the hemodialysis machine is unknown. Knowing this information would allow, if it is important enough, to add an additional parameter of citrate management by adapting the level of dialysis. The determination of citrate in an extracorporeal circulation circuit has already been performed and has been validated in the literature. We propose to perform the assay on subjects with the same starting parameters, in order to deduce the clearance of citrate.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 1, 2023
Est. primary completion date December 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Intensive care dialysis patients (Continuous Venous Hemofiltration with citrate). Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Citrate dosage
Patients are dialysed according to the standard of care. Biological variables are measured in pre-filter, post-filter and dialysate 30 minutes after the dialysis is initiated.

Locations

Country Name City State
Belgium CHU Brugmann Brussels

Sponsors (1)

Lead Sponsor Collaborator
Dr David DE BELS

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Citrate concentration - pre-filter Citrate concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Primary Citrate concentration - post-filter Citrate concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Primary Citrate concentration - dialysate Citrate concentration in a blood sample taken in the dialysate 30 minutes after the start of dialysis
Secondary Age Age Baseline
Secondary Weight Weight Baseline
Secondary Height Height Baseline
Secondary Sex Sex Baseline
Secondary Apache II score The APACHE II score is calculated at the beginning of the intensive care unit admission to help determine the patient's mortality risk for the admission. An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. Baseline
Secondary SOFA (Sequential Organ Failure Assessment) score The Sequential Organ Failure Assessment score (SOFA score), is used in intensive care units to determine and track the status of a patient with organ failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. Higher scores mean a higher risk of mortality. Baseline
Secondary Glomerular filtration rate (GFR) Glomerular filtration rate Baseline
Secondary Creatinin level Creatinin level Baseline
Secondary Diuresis Volume of urinary secretion in the last 12 hours Baseline
Secondary KDIGO classification The KDIGO classification defines 3 stages of increasing severity for acute kidney injuries. Baseline
Secondary Na (sodium) concentration -pre-filter Na (sodium) concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary Na (sodium) concentration -post-filter Na (sodium) concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary Cl (chlorine) concentration - pre-filter Cl (chlorine) concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary Cl (chlorine) concentration -post-filter Cl (chlorine) concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary K (potassium) concentration - pre-filter K (potassium) concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary K (potassium) concentration - post-filter K (potassium) concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary Total Ca (calcium) concentration -pre-filter Ca (calcium) concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary Total Ca (calcium) concentration -post-filter Ca (calcium) concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary Total Ca (calcium) concentration -dialysate Ca (calcium) concentration in the dialysate 30 minutes after the start of dialysis
Secondary Ionized calcium (Ca2+) concentration -pre-filter Ca (calcium) concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary Ionized calcium (Ca2+) concentration -post-filter Ca (calcium) concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary Ionized calcium (Ca2+) concentration -dialysate Ca (calcium) concentration in the dialysate 30 minutes after the start of dialysis
Secondary Mg (magnesium) concentration - pre-filter Mg (magnesium) concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary Mg (magnesium) concentration - post-filter Mg (magnesium) concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary PO4 (phosphate) concentration - pre-filter PO4 (phosphate) concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary PO4 (phosphate) concentration - post-filter PO4 (phosphate) concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary Lactate concentration - pre-filter Lactate blood concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary Lactate concentration - post-filter Lactate blood concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary Albumin concentration -pre-filter Albumin concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary Albumin concentration -post-filter Albumin concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary pH - pre-filter pH of a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary pH - post-filter pH of a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary Total C-reactive protein (CRP) -pre-filter Total CRP concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary Total C-reactive protein (CRP) -post-filter Total CRP concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary Total C-reactive protein (CRP) -dialysate Total CRP concentration in a blood sample taken in the dialysate 30 minutes after the start of dialysis
Secondary Monomeric C-reactive protein (CRP) -pre-filter Monomeric CRP concentration in a blood sample taken before the dialysis filter 30 minutes after the start of dialysis
Secondary Monomeric C-reactive protein (CRP) -post-filter Monomeric CRP concentration in a blood sample taken after the dialysis filter 30 minutes after the start of dialysis
Secondary Monomeric C-reactive protein (CRP) -dialysate Monomeric CRP concentration in a blood sample taken in the dialysate 30 minutes after the start of dialysis
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05031013 - Trace Elements Concentration in Dialysis
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT01685372 - Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults Phase 2
Active, not recruiting NCT01394770 - Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients Phase 4
Completed NCT00506441 - A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Phase 3
Completed NCT00537979 - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Phase 4
Completed NCT05415969 - CKD-aP Among Adults on Dialysis in Switzerland
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Active, not recruiting NCT01693263 - Outcome of BCF Access in Hemodialysis Patients
Completed NCT01421771 - Blood Pressure in Dialysis Patients N/A
Active, not recruiting NCT01065389 - Resistance Training in Intradialysis Patients Phase 2
Completed NCT00544492 - Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients Phase 4
Completed NCT03910426 - Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients
Completed NCT04565522 - Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers
Completed NCT04667741 - Post-dialysis Recovery Time and Affecting Factors Between Turkey and Portugal
Completed NCT04655989 - A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System N/A
Completed NCT05125848 - Clinical Evaluation of the CM-1500 During Hemodialysis N/A
Completed NCT04633915 - Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.
Completed NCT00767897 - The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients